PPIA
Peptidyl-prolyl cis-trans isomerase A
As of the edition of 20 October 2026, PPIA (peptidyl-prolyl cis-trans isomerase A, UniProt P62937) has 4 drugs tested at it and 13 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P62937
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 205
- Disease areas
- Blood and lymph; Immune system; Cancer; Inherited and neonatal; Heart and blood vessels; Infections; Eye; Skin and connective tissue
- Registered trials of its drugs
- 653
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cyclosporine | Marketed | Phase 4 | none listed |
| Alisporivir | Stopped | Phase 3 | none listed |
| LX201 | Stopped | Phase 3 | none listed |
| FOV1101-00 | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Engaged | 6 |
| Undetermined | 1 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Debiopharm | Route A |
| Santen | Route B |
The other 10 companies at PPIA
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at PPIA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.